{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T17:33:50Z","timestamp":1693762430994},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,2,15]]},"DOI":"10.2169\/internalmedicine.1194-18","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T22:30:16Z","timestamp":1539729016000},"page":"477-485","source":"Crossref","is-referenced-by-count":5,"title":["No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity"],"prefix":"10.2169","volume":"58","author":[{"given":"Takuya","family":"Hirosawa","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Miura","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Tahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Utsunomiya Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimitsu","family":"Murohisa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dokkyo Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukishige","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sano Kousei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nasu Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norikatsu","family":"Numao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Haga Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Utsunomiya Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Tano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shin-Oyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozue","family":"Murayama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Koga Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Kurata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tochigi Medical Center Shimotsuga, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwao","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Tochigi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukimura","family":"Fukaya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nasu Minami Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yoshizumi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kamitsuga General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Tsukui","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinari","family":"Takaoka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nomoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Isoda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tanaka J, Akita T, Ohisa M, et al. Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat 25: 363-372, 2018.","DOI":"10.1111\/jvh.12828"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Furusyo N, Kajiwara E, Takahashi K, et al. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study. J Gastroenterol Hepatol 23: 1094-1104, 2008.","DOI":"10.1111\/j.1440-1746.2008.05319.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kanda T, Imazeki F, Azemoto R, et al. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 56: 3335-3342, 2011.","DOI":"10.1007\/s10620-011-1750-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Murata C, Kondo T, Tamakoski K, Yatsuya H, Toyoshima H. Factors associated with life space among community-living rural elders in Japan. Public Health Nurs 23: 324-331, 2006.","DOI":"10.1111\/j.1525-1446.2006.00568.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Honda T, Katano Y, Shimizu J, et al. Efficacy of peginterferon-\u03b1-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 30: 527-537, 2010.","DOI":"10.1111\/j.1478-3231.2009.02064.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 21: 762-768, 2014.","DOI":"10.1111\/jvh.12312"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370: 1993-2001, 2014.","DOI":"10.1056\/NEJMoa1316145"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867-1877, 2013.","DOI":"10.1056\/NEJMoa1214854"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ogawa E, Furusyo N, Nomura H, et al. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antiviral Res 136: 37-44, 2016.","DOI":"10.1016\/j.antiviral.2016.10.012"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Atsukawa M, Tsubota A, Kondo C, et al. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis 49: 1029-1035, 2017.","DOI":"10.1016\/j.dld.2017.04.012"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kanda T, Nakamura M, Yasui S, et al. Treatment of real-world HCV genotype 2-infected Japanese patients with sofosbuvir plus ribavirin. Biology 6: 30, 2017.","DOI":"10.3390\/biology6020030"},{"key":"12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1186\/s12889-015-1891-2","volume":"15","author":"N Masaki","year":"2015","unstructured":"12. Masaki N, Yamagiwa Y, Shimbo T, et al. Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. BMC Public Health 15: 566, 2015.","journal-title":"BMC Public Health","ISSN":"http:\/\/id.crossref.org\/issn\/1471-2458","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Monnet E, Collin-Naudet E, Bresson-Hadni S, et al. Place of residence and distance to medical care influence the diagnosis of hepatitis C: a population-based study. J Hepatol 44: 499-506, 2006.","DOI":"10.1016\/j.jhep.2005.11.044"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Monnet E, Ram\u00e9e C, Minello A, Jooste V, Carel D, Di Martino V. Socioeconomic context, distance to primary care and detection of hepatitis C: a French population-based study. Soc Sci Med 66: 1046-1056, 2008.","DOI":"10.1016\/j.socscimed.2007.11.044"},{"key":"15","unstructured":"15. Sato T. Efficacy of peginterferon a-2b and ribavirin (PEG\/RIBA) combination therapy in patients with chronic hepatitis C in Tochigi-Multicenter-retrospective study. Clinic All-Round 60: 800-805, 2011."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Iio E, Shimada N, Takaguchi K, et al. Clinical evaluation of sofosbuvir\/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir\/asunaprevir therapy. Hepatol Res 47: 1308-1316, 2017.","DOI":"10.1111\/hepr.12898"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Butt AA, Ren Y, Lo Re V, Taddei TH, Kaplan DE. Comparing child-pugh, MELD, and FIB-4 to predict clinical outcomes in hepatitis C virus-infected persons: results from ERCHIVES. Clin Infect Dis 65: 64-72, 2017.","DOI":"10.1093\/cid\/cix224"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Suh B, Park S, Shin DW, et al. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology 61: 1261-1268, 2015.","DOI":"10.1002\/hep.27654"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373: 2608-2617, 2015.","DOI":"10.1056\/NEJMoa1512612"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/4\/58_1194-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T04:45:07Z","timestamp":1550292307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/4\/58_1194-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1194-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]}}}